GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (NSE:DIVISLAB) » Definitions » Gross Profit

Divi's Laboratories (NSE:DIVISLAB) Gross Profit : ₹43,362 Mil (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories Gross Profit?

Divi's Laboratories's gross profit for the three months ended in Dec. 2023 was ₹11,260 Mil. Divi's Laboratories's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was ₹43,362 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Divi's Laboratories's gross profit for the three months ended in Dec. 2023 was ₹11,260 Mil. Divi's Laboratories's Revenue for the three months ended in Dec. 2023 was ₹18,550 Mil. Therefore, Divi's Laboratories's Gross Margin % for the quarter that ended in Dec. 2023 was 60.70%.

Divi's Laboratories had a gross margin of 60.70% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Divi's Laboratories was 66.28%. The lowest was 58.67%. And the median was 61.53%.


Divi's Laboratories Gross Profit Historical Data

The historical data trend for Divi's Laboratories's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Divi's Laboratories Gross Profit Chart

Divi's Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29,786.00 31,826.30 45,342.60 58,320.90 46,122.20

Divi's Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,690.00 10,212.20 10,900.00 10,990.00 11,260.00

Competitive Comparison of Divi's Laboratories's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Gross Profit distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's Gross Profit falls into.



Divi's Laboratories Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Divi's Laboratories's Gross Profit for the fiscal year that ended in Mar. 2023 is calculated as

Gross Profit (A: Mar. 2023 )=Revenue - Cost of Goods Sold
=76659.4 - 30537.2
=46,122

Divi's Laboratories's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=18550 - 7290
=11,260

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹43,362 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Divi's Laboratories's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=11,260 / 18550
=60.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Divi's Laboratories  (NSE:DIVISLAB) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Divi's Laboratories had a gross margin of 60.70% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Divi's Laboratories Gross Profit Related Terms

Thank you for viewing the detailed overview of Divi's Laboratories's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Divi's Laboratories (NSE:DIVISLAB) Business Description

Traded in Other Exchanges
Address
Divi Towers, 1-72/23(P)/DIVIS/303, Babukhan Lane, Cyber Hills, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. The company has three distinct business segments: Generic APIs, Custom Synthesis, and Nutraceuticals. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Divi's Laboratories (NSE:DIVISLAB) Headlines

No Headlines